Show simple item record

dc.contributor.authorTrevisani, F
dc.contributor.authorGhidini, M
dc.contributor.authorLarcher, A
dc.contributor.authorLampis, A
dc.contributor.authorLote, H
dc.contributor.authorManunta, P
dc.contributor.authorAlibrandi, MTS
dc.contributor.authorZagato, L
dc.contributor.authorCitterio, L
dc.contributor.authorDell'Antonio, G
dc.contributor.authorCarenzi, C
dc.contributor.authorCapasso, G
dc.contributor.authorRugge, M
dc.contributor.authorRigotti, P
dc.contributor.authorBertini, R
dc.contributor.authorCascione, L
dc.contributor.authorBriganti, A
dc.contributor.authorSalonia, A
dc.contributor.authorBenigni, F
dc.contributor.authorBraconi, C
dc.contributor.authorFassan, M
dc.contributor.authorHahne, JC
dc.contributor.authorMontorsi, F
dc.contributor.authorValeri, N
dc.date.accessioned2017-04-03T09:40:44Z
dc.date.issued2016-11-01
dc.identifier.citationBritish journal of cancer, 2016, 115 (11), pp. 1343 - 1350
dc.identifier.issn0007-0920
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/541
dc.identifier.eissn1532-1827
dc.identifier.doi10.1038/bjc.2016.329
dc.description.abstractBACKGROUND: A significant proportion of patients undergoing radical nephrectomy (RN) for clear-cell renal cell carcinoma (RCC) develop chronic kidney disease (CKD) within a few years following surgery. Chronic kidney disease has important health, social and economic impact and no predictive biomarkers are currently available. MicroRNAs (miRs) are small non-coding RNAs implicated in several pathological processes. METHODS: Primary objective of our study was to define miRs whose deregulation is predictive of CKD in patients treated with RN. Ribonucleic acid from formalin-fixed paraffin embedded renal parenchyma (cortex and medulla isolated separately) situated >3 cm from the matching RCC was tested for miR expression using nCounter NanoString technology in 71 consecutive patients treated with RN for RCC. Validation was performed by RT-PCR and in situ hybridisation. End point was post-RN CKD measured 12 months post-operatively. Multivariable logistic regression and decision curve analysis were used to test the statistical and clinical impact of predictors of CKD. RESULTS: The overexpression of miR-193b-3p was associated with high risk of developing CKD in patients undergoing RN for RCC and emerged as an independent predictor of CKD. The addition of miR-193b-3p to a predictive model based on clinical variables (including sex and estimated glomerular filtration rate) increased the sensitivity of the predictive model from 81 to 88%. In situ hybridisation showed that miR-193b-3p overexpression was associated with tubule-interstitial inflammation and fibrosis in patients with no clinical or biochemical evidence of pre-RN nephropathy. CONCLUSIONS: miR-193b-3p might represent a useful biomarker to tailor and implement surveillance strategies for patients at high risk of developing CKD following RN.
dc.formatPrint-Electronic
dc.format.extent1343 - 1350
dc.languageeng
dc.language.isoeng
dc.publisherSPRINGERNATURE
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectHumans
dc.subjectCarcinoma, Renal Cell
dc.subjectKidney Neoplasms
dc.subjectMicroRNAs
dc.subjectGlomerular Filtration Rate
dc.subjectNephrectomy
dc.subjectBiomarkers, Tumor
dc.titleMicroRNA 193b-3p as a predictive biomarker of chronic kidney disease in patients undergoing radical nephrectomy for renal cell carcinoma.
dc.typeJournal Article
dcterms.dateAccepted2016-09-22
rioxxterms.versionofrecord10.1038/bjc.2016.329
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2016-11
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBritish journal of cancer
pubs.issue11
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Signal Transduction & Molecular Pharmacology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Evolutionary Genomics & Modelling
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Gastrointestinal Cancer Biology and Genomics
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Signal Transduction & Molecular Pharmacology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Evolutionary Genomics & Modelling
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Gastrointestinal Cancer Biology and Genomics
pubs.publication-statusPublished
pubs.volume115
pubs.embargo.termsNo embargo
icr.researchteamSignal Transduction & Molecular Pharmacology
icr.researchteamEvolutionary Genomics & Modelling
icr.researchteamGastrointestinal Cancer Biology and Genomics
dc.contributor.icrauthorLampis, Andrea
dc.contributor.icrauthorLote, Hazel
dc.contributor.icrauthorBraconi, Chiara
dc.contributor.icrauthorHahne, Jens
dc.contributor.icrauthorValeri, Nicola


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0